Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. (ABOS): 3 pipeline candidates · 1 upcoming catalyst · ~16 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
15.7 months
D/E 0.53 · 0% dilution
Lead: Phase 2
3 candidates
1 upcoming, next in ~196d
0 buys · 44 sells (180d)
A transparent, data-derived signal for Acumen Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$162.5M
Cash
$52.0M
Quarterly Burn
$24.1M
Runway
15.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| ebd therapy | Preclinical |
| sabirnetug | Phase 2 |
| sabirnetug (ACU193) | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
82
Total value held
$95.2M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 20,992,669 | $49.5M |
| vanguard capital management llc | 3,012,554 | $7.1M |
| alyeska investment group, l.p. | 2,454,754 | $5.8M |
| franklin resources inc | 2,305,096 | $5.4M |
| adar1 capital management, llc | 2,156,334 | $5.1M |
| fmr llc | 1,157,346 | $2.7M |
| hudson bay capital management lp | 968,940 | $2.3M |
| pathstone holdings, llc | 859,110 | $2.0M |
| susquehanna international group, llp | 713,376 | $1.7M |
| millennium management llc | 659,675 | $1.6M |
Showing top 10 of 82 institutional holders of Acumen Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Acumen Pharmaceuticals, Inc.'s pipeline?
Acumen Pharmaceuticals, Inc. (ABOS) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Acumen Pharmaceuticals, Inc.'s lead drug candidate?
Acumen Pharmaceuticals, Inc.'s most advanced tracked candidate is ebd therapy (Preclinical) for Alzheimer's disease.
What is Acumen Pharmaceuticals, Inc.'s next catalyst?
Acumen Pharmaceuticals, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: sabirnetug" — expected December 31, 2026.
What is Acumen Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Acumen Pharmaceuticals, Inc. has approximately 15.7 months of cash runway.
What is Acumen Pharmaceuticals, Inc.'s market capitalization?
Acumen Pharmaceuticals, Inc.'s market capitalization is approximately $162.5M.
Get the full picture on Acumen Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.